MONITILLO, LUIGIA
 Distribuzione geografica
Continente #
NA - Nord America 1.430
EU - Europa 791
AS - Asia 326
AF - Africa 15
SA - Sud America 4
OC - Oceania 2
Totale 2.568
Nazione #
US - Stati Uniti d'America 1.415
CN - Cina 224
IT - Italia 128
AT - Austria 109
SE - Svezia 100
IE - Irlanda 98
FR - Francia 81
FI - Finlandia 62
DK - Danimarca 52
DE - Germania 42
UA - Ucraina 41
KR - Corea 30
SG - Singapore 30
PL - Polonia 22
GB - Regno Unito 20
SN - Senegal 15
VN - Vietnam 14
BE - Belgio 13
CA - Canada 13
IN - India 13
GR - Grecia 12
SA - Arabia Saudita 6
RU - Federazione Russa 4
UZ - Uzbekistan 4
BR - Brasile 3
ES - Italia 3
AU - Australia 2
NL - Olanda 2
PR - Porto Rico 2
CH - Svizzera 1
CL - Cile 1
IL - Israele 1
IR - Iran 1
KH - Cambogia 1
MD - Moldavia 1
PH - Filippine 1
TR - Turchia 1
Totale 2.568
Città #
Chandler 226
Beijing 166
Ann Arbor 115
Vienna 109
Dublin 97
Ashburn 86
Dearborn 68
Fairfield 64
Villeurbanne 61
Wilmington 61
Houston 56
Woodbridge 53
Nyköping 46
Torino 45
Medford 37
Jacksonville 31
Princeton 30
San Mateo 28
Warsaw 22
Cambridge 20
Pisa 20
Fremont 19
Guangzhou 17
Seattle 17
Milan 15
Brussels 13
Singapore 12
Dong Ket 10
Turin 10
New York 9
Toronto 9
Washington 9
Boardman 8
Hefei 7
Pune 7
Boston 6
Nanjing 6
Norwalk 6
Wayne 6
Düsseldorf 5
Helsinki 4
Mcallen 4
Munich 4
Philadelphia 4
San Jose 4
Auburn Hills 3
Chengdu 3
Florence 3
Los Angeles 3
Phoenix 3
Redwood City 3
San Diego 3
Coimbatore 2
Des Moines 2
Flushing 2
Mountain View 2
Nanchang 2
Naples 2
Ottawa 2
Recife 2
Saint Petersburg 2
San Francisco 2
Shaoxing 2
Taranto 2
Zhengzhou 2
Ardabil 1
Arlington 1
Baltimore 1
Baotou 1
Bari 1
Berlin 1
Bilbao 1
Borgaro Torinese 1
Borgo San Dalmazzo 1
Changsha 1
Chaoyang 1
Chicago 1
Chisinau 1
Dallas 1
Delhi 1
Duncan 1
Falls Church 1
Fort Belvoir 1
Fuzhou 1
Grevenbroich 1
Groningen 1
Hangzhou 1
Hebei 1
Jinan 1
Kunming 1
Köln 1
Madrid 1
Makati City 1
Massapequa Park 1
Ningbo 1
Noto 1
Nuremberg 1
Odesa 1
Omegna 1
Padova 1
Totale 1.734
Nome #
HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data 376
Prospective molecular monitoring of minimal residual disease after nonmyeloablative allografting in newly diagnosed multiple myeloma 193
Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: evidence for premature aging of the myeloid compartment. 123
High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma 122
TELOMERES SHORTEN DURING CHRONIC LYMPHOCYTIC LEUKEMIA(CLL) EVOLUTION: AN ANALYSIS ON 88 CASES 112
Ficoll-hypaque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis 105
Cells carrying nonlymphoma-associated bcl-2/IgH rearrangements (NLABR) are phenotypically related to follicular lymphoma and can establish as long-term persisting clonal populations 97
Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR 96
Telomere lenght measurement in the clinically oriented research setting: a comparison between Southern blot (SB), real time quantitative PCR (RQ-PCR) and FLOW-FISH (FF) 87
Telomere length is an independent predictor of survival, treatment requirement and Richter’s syndrome transformation in chronic lymphocytic leukemia 87
High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma 85
Expression of telomeric proteins in chronic lymphocytic leukemia (CLL) 84
Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: Evidences from long term follow-up 77
Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial 76
Comparison of two real-time quantitative polymerase chain reaction strategies for minimal residual disease evaluation in lymphoproliferative disorders: correlation between immunoglobulin gene mutation load and real-time quantitative polymerase chain reaction performance. 74
Comparison of different DNA extraction methods from peripheral blood cells: advices from the Fondazione Italiana Linfomi - MRD Network. 74
LONG-TERM RESULTS of the GIMEMA VTD Consolidation TRIAL In Autografted MULTIPLE Myeloma PATIENTS (VEL-03-096): IMPACT of Minimal RESIDUAL DISEASE Detection by REAL Time Quantitative PCR On LATE Recurrences and Overall SURVIVAL 73
Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome 70
Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders 68
Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia 68
MINIMAL RESIDUAL DISEASE (MRD) DETECTION BY NEXT GENERATION SEQUENCING AND REAL TIME QUANTITATIVE–PCR: A METHODICAL COMPARISON IN ALL, MCL AND MM 66
null 64
Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients 62
Overexpression of Bcl-2 by activated human hepatic stellate cells: resistance to apoptosis as a mechanism of progressive hepatic fibrogenesis in humans 60
Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells 58
COMPARISON OF DIFFERENT RQ-PCR DESIGN STRATEGIES FOR MINIMAL RESIDUAL DISEASE DETECTION IN LYMPHOPROLIFERATIVE DISORDERS: CORRELATION BETWEEN IMMUNOGLOBULIN GENE MUTATION LOAD AND RQ-PCR PERFORMANCE 54
HIGH RATES OF PROLONGED MOLECULAR REMISSIONS AFTER TANDEM AUTOLOGOUS-NONMYELOABLATIVE ALLOGRAFTING IN NEWLY DIAGNOSED MYELOMA 50
A COMPARATIVE ANALYSIS OF NEXT GENERATION SEQUENCING AND REAL TIME QUANTITATIVE–PCR FOR MINIMAL RESIDUAL DEECTION IN FOLLICULAR LYMPHOMA 48
Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma 38
Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma. 17
Molecular evaluation of Minimal Residual Disease and clinical impact analysis in the phase III study FIL MCL0208 1
Totale 2.665
Categoria #
all - tutte 7.234
article - articoli 0
book - libri 0
conference - conferenze 2.412
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.646


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020415 9 8 20 64 30 69 64 25 33 33 41 19
2020/2021294 39 22 23 18 25 11 20 15 28 18 45 30
2021/2022353 9 6 2 19 7 13 66 22 9 28 106 66
2022/2023593 60 65 13 69 47 134 32 37 59 35 17 25
2023/2024243 28 70 20 10 16 52 0 12 0 4 7 24
2024/20252 2 0 0 0 0 0 0 0 0 0 0 0
Totale 2.665